Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.30K | 198.50K | -65.90K | -180.20K | 1.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.30K | 198.50K | -65.90K | -180.20K | 1.44M |
| Cost of Revenue | 433.20K | 146.00K | 531.90K | 794.70K | 2.74M |
| Gross Profit | -319.00K | 52.40K | -597.90K | -974.90K | -1.30M |
| SG&A Expenses | 1.35M | 857.60K | 822.10K | 853.10K | 917.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.79M | 1.00M | 1.35M | 1.65M | 3.66M |
| Operating Income | -1.67M | -805.20K | -1.42M | -1.83M | -2.22M |
| Income Before Tax | -1.92M | -1.10M | -1.72M | -2.19M | -2.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.92 | -1.10 | -1.72 | -2.19 | -2.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | -1.10M | -1.72M | -2.19M | -2.61M |
| EBIT | -1.67M | -805.20K | -1.42M | -1.83M | -2.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.03 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 263.19M | 262.02M | 257.29M | 253.93M | 251.22M |
| Average Diluted Shares Outstanding | 263.19M | 262.02M | 257.29M | 253.93M | 251.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |